The Weight of Inequality: GLP 1s' Promising Future Clouded by Cost and Access The medical landscape has undergone significant changes in recent years, largely due to the introduction of GLP 1 drugs such as Ozempic, Wegovy, and Zepbound.
These medications have revolutionized obesity treatment by shifting focus from late stage interventions to proactive weight management that can prevent disease before it starts.
According to Robin Wenzel, head of Wells Fargo Industry Insights, GLP 1s have "broken the script" on obesity treatment, highlighting a more pressing issue than the disease itself: who can afford to wait for them to take effect.